Work

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.2061

Authors: Annick Desjardins, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, Susan Boulton, Denise Lally-Goss, Frances McSherry, Eric S Lipp, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, Matthias Gromeier

Institution: Duke Medical Center

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891592686

Cites:

Cited by: 21

Related to: 10